Sus Clinicals specializes in advancing cancer research through its innovative Oncopig® platform, which utilizes genetically modified pigs to create a more predictive model for preclinical testing. This platform allows researchers to induce tumors and comorbidities on demand, facilitating the evaluation of drugs, diagnostics, and medical devices in a setting that closely mimics human physiology. By bridging the gap between traditional mouse models and human clinical trials, Sus Clinicals aims to enhance the efficiency and effectiveness of therapeutic development, ultimately saving time and resources in the quest for life-saving cancer treatments.

The company offers a comprehensive range of products and services, including a biorepository of validated cell lines derived from the Oncopig model, histology services, and fresh or frozen tissue samples. Their capabilities extend to cloud-based data storage solutions for managing porcine electronic medical records and digital imaging, as well as support for Good Laboratory Practices (GLP) studies. With a focus on collaboration with leading research institutions, Sus Clinicals is committed to providing researchers with the tools and expertise necessary to advance their work in cancer therapeutics and beyond.

United States

Sus Clinicals solves major problems in qualifying new cancer drugs, devices, diagnostics and therapies.  Using a proprietary model of testing on genetically-modified pigs pioneered at the University of Illinois, Sus Clinicals leverages the inherent advantages of a patent-pending large animal testing methodology combined with novel clinical approaches to reduce false positives, model the interactions of multiple diseases, and accelerate progress toward human trials for the most promising therapies.


Sus Clinicals

Company Details